<?xml version='1.0' encoding='utf-8'?>
<document id="24380714"><sentence text="In vitro identification of cytochrome P450 isoforms responsible for the metabolism of 1-hydroxyl-2,3,5-trimethoxy-xanthone purified from Halenia elliptica D. Don."><entity charOffset="86-122" id="DDI-PubMed.24380714.s1.e0" text="1-hydroxyl-2,3,5-trimethoxy-xanthone" /></sentence><sentence text="1-Hydroxyl-2,3,5-trimethoxyxanthone (HM-1) is one of the main constituents extracted from Halenia elliptica D"><entity charOffset="0-35" id="DDI-PubMed.24380714.s2.e0" text="1-Hydroxyl-2,3,5-trimethoxyxanthone" /><entity charOffset="37-41" id="DDI-PubMed.24380714.s2.e1" text="HM-1" /><pair ddi="false" e1="DDI-PubMed.24380714.s2.e0" e2="DDI-PubMed.24380714.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24380714.s2.e0" e2="DDI-PubMed.24380714.s2.e1" /></sentence><sentence text=" Don, which is a traditionally used Tibetan medicinal plant" /><sentence text=" The aim of this study was to illustrate the proposed metabolic pathways of HM-1 and identify which cytochrome P450 (CYP450) isoforms involved in its metabolism by using pooled human liver microsomes (HLMs) and recombinant CYP450 isoforms with selective chemical inhibitors"><entity charOffset="76-79" id="DDI-PubMed.24380714.s4.e0" text="HM-1" /></sentence><sentence text=" Metabolites were identified by high performance liquid chromatography coupled to ion trap time-of-flight mass spectrometry (LCMS(n)-ESI-IT-TOF) and nuclear magnetic resonance spectroscopy (hydrogen-1 NMR and carbon-13 NMR)" /><sentence text=" Three metabolites (M1-M3) were identified, which demonstrated that demethylation and hydroxylation were the major Phase I metabolic reactions for HM-1 in HLMs"><entity charOffset="147-150" id="DDI-PubMed.24380714.s6.e0" text="HM-1" /></sentence><sentence text=" The structure of another metabolite (M4) was still unclear" /><sentence text=" The enzymatic kinetics of M1 (K(m)=23" /><sentence text="19±14" /><sentence text="20 μM) and M2 (Km=32" /><sentence text="06±17" /><sentence text="09 μM) exhibited substrate inhibition; whereas, the formation of M3 (K(m)=5" /><sentence text="73±0" /><sentence text="70 μM) and M4 (K(m)=16" /><sentence text="43±5" /><sentence text="12 μM) displayed Michaelis-Menten kinetics" /><sentence text=" The intrinsic clearance (V(max)/K(m)) of M3 was highest among these metabolites, suggesting that M3 was the major metabolite of HM-1"><entity charOffset="129-132" id="DDI-PubMed.24380714.s17.e0" text="HM-1" /></sentence><sentence text=" Moreover, CYP3A4 and CYP2C8 were the primary CYP450 isoform responsible for the metabolism of HM-1"><entity charOffset="95-98" id="DDI-PubMed.24380714.s18.e0" text="HM-1" /></sentence><sentence text=" CYP1A2, CYP2A6, CYP2B6, CYP2C9 and CYP2C19 were also involved in HM-1 metabolism, especially in the formation of M3"><entity charOffset="66-69" id="DDI-PubMed.24380714.s19.e0" text="HM-1" /></sentence><sentence text=" This study finally provides evidence of substrate inhibition and metabolism-based drug-drug interaction for the medicinal preparations containing HM-1 used in clinic"><entity charOffset="147-150" id="DDI-PubMed.24380714.s20.e0" text="HM-1" /></sentence><sentence text="" /></document>